The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Schmitt Ney, Michel ^a   Camussi, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PAX3 FOXO1 FUSION PROTEIN; SMAD PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR PAX3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; ONCOPROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, HUMAN; PAX3-FOXO1A FUSION PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; CELL DIFFERENTIATION; CELL LINE; GENE TRANSLOCATION; GENETICS; HEK293 CELL LINE; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTORS; HEK293 CELLS; HUMANS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PAX3 TRANSCRIPTION FACTOR; RHABDOMYOSARCOMA; TRANSFORMING GROWTH FACTOR BETA; TRANSLOCATION, GENETIC;

EID: 84926328807     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121474     Document Type: Article

References (53)

1. Ferrari A, Sultan I, Huang TT, Rodriguez-Galindo C, Shehadeh A, Meazza C, et al. Soft tissue sarcoma across the age spectrum: A population-based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer. 2011; 57: 943-949. doi: 10.1002/pbc.23252 PMID: 21793180
2. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ 3rd, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 5: 230-235. PMID: 8275086
3. Mercado GE, Barr FG. Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. Curr Mol Med. 2007; 7: 47-61. PMID: 17311532
4. Linardic CM. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett. 2008; 270: 10-18. doi: 10.1016/j.canlet.2008.03.035 PMID: 18457914
5. Buckingham M, Relaix F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu Rev Cell Dev Biol. 2007; 23: 645-673. PMID: 17506689
6. Scuoppo C, Riess I, Schmitt-Ney M, Allegra P, Forni PE, Bersani F, et al. The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes. Exp Cell Res. 2007; 313: 2308-2317. PMID: 17490646
7. Graf Finckenstein F, Shahbazian V, Davicioni E, Ren YX, Anderson MJ. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene. 2008; 27: 2004-2014. PMID: 17922034
8. Lagutina I, Conway SJ, Sublett J, Grosveld GC. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol Cell Biol. 2002; 22: 7204-7216. PMID: 12242297
9. Anderson MJ, Shelton GD, Cavenee WK, Arden KC. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci U S A. 2001; 98: 1589-1594. PMID: 11171995
10. Massague J. TGFbeta in Cancer. Cell. 2008; 134: 215-230. doi: 10.1016/j.cell.2008.07.001 PMID: 18662538
11. Seoane J, Le HV, Shen L, Anderson SA, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004; 117: 211-223. PMID: 15084259
12. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 2006; 10: 203-214. PMID: 16959612
13. Gomis RR, Alarcon C, He W, Wang Q, Seoane J, Lash A, et al. A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci U S A. 2006; 103: 12747-12752. PMID: 16908841
14. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005; 24: 7410-7425. PMID: 16288288
15. Dansen TB, Burgering BM. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008; 18: 421-429. doi: 10.1016/j.tcb.2008.07.004 PMID: 18715783
16. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007; 128: 325-339. PMID: 17254970
17. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007; 128: 309-323. PMID: 17254969
18. Lollini PL, De Giovanni C, Landuzzi L, Nicoletti G, Scotlandi K, Nanni P. Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells. Invasion Metastasis. 1991; 11: 116-124. PMID: 1917385
19. Ye L, Zhang HY, Wang H, Yang GH, Bu H, Zhang L, et al. Effects of transforming growth factor beta 1 on the growth of rhabdomyosarcoma cell line RD. Chin Med J (Engl). 2005; 118: 678-686. PMID: 15899124
20. Hettmer S, Wagers AJ. Muscling in: Uncovering the origins of rhabdomyosarcoma. Nat Med. 2010; 16: 171-173. doi: 10.1038/nm0210-171 PMID: 20134473
21. Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett. 2009; 279: 126-136. doi: 10.1016/j.canlet.2008.09.039 PMID: 19008039
22. Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y, et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun. 2008; 365: 568-574. PMID: 18022385
23. Hecker RM, Amstutz RA, Wachtel M, Walter D, Niggli FK, Schafer BW. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene. 2010; 29: 3942-3952. doi: 10.1038/onc.2010.145 PMID: 20453878
24. Jung YA, Lee KM, Kim MK, Jung GS, Seo YJ, Kim HS, et al. Forkhead transcription factor FoxO1 inhibits insulin- and transforming growth factor-beta-stimulated plasminogen activator inhibitor-1 expression. Biochem Biophys Res Commun. 2009; 386: 757-761. doi: 10.1016/j.bbrc.2009.06.124 PMID: 19563779
25. Dimova EY, Samoylenko A, Kietzmann T. FOXO4 induces human plasminogen activator inhibitor-1 gene expression via an indirect mechanism by modulating HIF-1alpha and CREB levels. Antioxid Redox Signal. 2010; 13: 413-424. doi: 10.1089/ars.2009.2999 PMID: 20136501
26. Jag UR, Zavadil J, Stanley FM. Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1. Mol Endocrinol. 2009; 23: 1587-1602. doi: 10.1210/me.2008-0421 PMID: 19608644
27. Yamada T, Ozaki N, Kato Y, Miura Y, Oiso Y. Insulin downregulates angiopoietin-like protein 4 mRNA in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2006; 347: 1138-1144. PMID: 16870142
28. Furuyama T, Nakazawa T, Nakano I, Mori N. Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J. 2000; 349: 629-634. PMID: 10880363
29. Stopa M, Anhuf D, Terstegen L, Gatsios P, Gressner AM, Dooley S. Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. J Biol Chem. 2000; 275: 29308-29317. PMID: 10887185
30. Essaghir A, Dif N, Marbehant CY, Coffer PJ, Demoulin JB. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem. 2009; 284: 10334-10342. doi: 10.1074/jbc.M808848200 PMID: 19244250
31. Al-Mubarak B, Soriano FX, Hardingham GE. Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin). 2009; 3: 233-238. PMID: 19690465
32. Zhou J, Liao W, Yang J, Ma K, Li X, Wang Y, et al. FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway. Autophagy. 2012; 8: 1712-1723. doi: 10.4161/auto.21830 PMID: 22931788
33. Wang L, Brugge JS, Janes KA. Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci U S A. 2011; 108: E803-812. doi: 10.1073/pnas.1103423108 PMID: 21873240
34. Tang ED, Nunez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem. 1999; 274: 16741-16746. PMID: 10358014
35. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8: 627-644. doi: 10.1038/nrd2926 PMID: 19644473
36. Bouchard C, Marquardt J, Bras A, Medema RH, Eilers M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J. 2004; 23: 2830-2840. PMID: 15241468
37. Bouchard C, Lee S, Paulus-Hock V, Loddenkemper C, Eilers M, Schmitt CA. FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev. 2007; 21: 2775-2787. PMID: 17974917
38. del Peso L, Gonzalez VM, Hernandez R, Barr FG, Nunez G. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene. 1999; 18: 7328-7333. PMID: 10602488
39. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001; 20: 5736-5746. PMID: 11607823
40. Cahill MA, Ernst WH, Janknecht R, Nordheim A. Regulatory squelching. FEBS Lett. 1994; 344: 105-108. PMID: 8187867
41. Xia SJ, Holder DD, Pawel BR, Zhang C, Barr FG. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Am J Pathol. 2009; 175: 2600-2608. doi: 10.2353/ajpath.2009.090192 PMID: 19893043
42. Keller C, Hansen MS, Coffin CM, Capecchi MR. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev. 2004; 18: 2608-2613. PMID: 15520281
43. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 2004; 18: 2614-2626. PMID: 15489287
44. Ebauer M, Wachtel M, Niggli FK, Schafer BW. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene. 2007; 26: 7267-7281. PMID: 17525748
45. So CW, Cleary ML. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Mol Cell Biol. 2002; 22: 6542-6552. PMID: 12192052
46. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell. 2002; 2: 81-91. PMID: 12150827
47. Jensen KS, Binderup T, Jensen KT, Therkelsen I, Borup R, Nilsson E, et al. FoxO3A promotes metabolic adaptation to hypoxia by antagonizing Myc function. EMBO J. 2001; 30: 4554-4570.
48. Czymai T, Viemann D, Sticht C, Molema G, Goebeler M, Schmidt M. FOXO3 modulates endothelial gene expression and function by classical and alternative mechanisms. J Biol Chem. 2010; 285: 10163-10178. doi: 10.1074/jbc.M109.056663 PMID: 20123982
49. Bois PR, Grosveld GC. FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts. EMBO J. 2003; 22: 1147-1157. PMID: 12606579
50. Sun Q, Zhang Y, Yang G, Chen X, Cao G, Wang J, et al. Transforming growth factor-beta-regulated miR-24 promotes skeletal muscle differentiation. Nucleic Acids Res. 2008; 36: 2690-2699. doi: 10.1093/nar/gkn032 PMID: 18353861
51. Wang S, Guo L, Dong L, Li S, Zhang J, Sun M. TGF-beta1 signal pathway may contribute to rhabdomyosarcoma development by inhibiting differentiation. Cancer Sci. 2010; 101: 1108-1116. doi: 10.1111/j.1349-7006.2010.01512.x PMID: 20219075
52. Sun MM, Li JF, Guo LL, Xiao HT, Dong L, Wang F, et al. TGF-beta1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma. Oncogene. 2014; 33: 2075-2086. doi: 10.1038/onc.2013.165 PMID: 23665678
53. Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol. 2013; 3: 183. doi: 10.3389/fonc.2013.00183 PMID: 23882450